Clinical Trial Update: Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating momelotinib in combination with capecitabine and oxaliplatin for relapsed/refractory metastatic pancreatic ductal adenocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Momelotinib (momelotinib)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: TERMINATED